Keith R McCain
Overview
Explore the profile of Keith R McCain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
179
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhandari N, Day K, Payakachat N, Franks A, McCain K, Ragland D
Womens Health Issues
. 2018 Mar;
28(3):251-257.
PMID: 29588116
Introduction: Given the rapid rise in availability and use, understanding the perception of electronic nicotine delivery systems (ENDS) products in pregnant women is vital. As more women of reproductive age...
2.
Patton A, Seely K, Yarbrough A, Fantegrossi W, James L, McCain K, et al.
Biochem Biophys Res Commun
. 2018 Mar;
498(3):597-602.
PMID: 29522717
Synthetic cannabinoids (SCBs), synonymous with 'K2', 'Spice' or 'synthetic marijuana', are psychoactive drugs of abuse that frequently result in clinical effects and toxicity more severe than those classically associated with...
3.
Franks A, Hawes W, McCain K, Payakachat N
Curr Pharm Teach Learn
. 2017 Dec;
9(6):1003-1009.
PMID: 29233367
Introduction: Our study evaluated the electronic cigarette (e-cigarette) use, knowledge, and perceptions of health professional students enrolled in one of five colleges at a single academic health center. Methods: A...
4.
Seely K, Patton A, Moran C, Womack M, Prather P, Fantegrossi W, et al.
Forensic Sci Int
. 2013 Dec;
233(1-3):416-22.
PMID: 24314548
New designer drugs such as K2, Spice, and "bath salts" present a formidable challenge for law enforcement and public health officials. The following report summarizes a three-year study of 1320...
5.
Fantegrossi W, McCain K, Moran J, Hoffman R
J Pediatr
. 2013 Oct;
163(6):1797-8.
PMID: 24128645
No abstract available.
6.
Patton A, Seely K, Chimalakonda K, Tran J, Trass M, Miranda A, et al.
Anal Chem
. 2013 Aug;
85(19):9390-9.
PMID: 23987522
Designer synthetic cannabinoids like JWH-018 and AM2201 have unique clinical toxicity. Cytochrome-P450-mediated metabolism of each leads to the generation of pharmacologically active (ω)- and (ω-1)-monohydroxyl metabolites that retain high affinity...
7.
Patton A, Chimalakonda K, Moran C, McCain K, Radominska-Pandya A, James L, et al.
J Forensic Sci
. 2013 Jul;
58(6):1676-80.
PMID: 23822805
Limited forensic and clinical experience and the lack of confirmatory testing strategies for synthetic cannabinoids (SC) prevent adequate characterization of SC toxicity and the potential impact on public health. A...
8.
Franks A, Schmidt J, McCain K, Fraer M
Ann Pharmacother
. 2012 Feb;
46(2):192-9.
PMID: 22298600
Background: Cardiovascular events associated with energy drink consumption have been reported, but few data exist to delineate the hemodynamic effects of energy drinks. Objective: To compare the effects of an...
9.
McCain K, Sawyer T, Spiller H
Ann Pharmacother
. 2007 Sep;
41(10):1632-7.
PMID: 17848422
Background: There are 4 centrally acting cholinesterase inhibitors (CA-ChEI) available in the US: tacrine, galantamine, rivastigmine, and donepezil. Documented clinical experience involving exposure to these agents is limited. The lack...